Navigation Links
Barr's Generic Version of Estrostep(R) Fe Tablets Approved

Company To Launch Generic Version of Estrostep Fe Under TriLegest(TM) Fe


WOODCLIFF LAKE, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market a generic version of Warner Chilcott Company, Inc.'s Estrostep(R) Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) oral contraceptive product. The Company will launch its product immediately under the tradename TriLegest(TM) Fe. The Company's generic oral contraceptive portfolio will now contain 25 products.

In April 2004, Warner Chilcott and Barr entered into an agreement to settle patent litigation under which Warner Chilcott granted Barr a non- exclusive license to launch a generic version of Estrostep Fe in October 2007, six months prior to the last patent expiration on Estrostep Fe.

Estrostep Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Estrostep Fe is also indicated for the treatment of moderate acne vulgaris in females, .15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Estrostep Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months.

Estrostep Fe had annual sales of approximately $110 million for the twelve months ending August 2007, based on IMS data.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 115 generic and 25 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Generic drug costs remain shackled
2. FDA Approves Indian Generic Drug For AIDS Treatment
3. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
4. AIDS Generic Drugs Approved by FDA for Sale in US
5. HIV Mortality declining in India due to Generic Antiretroviral therapy drugs
6. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
7. India to produce Tamiflu generic ‘Oseltamivir
8. US FDA approved Aurobindo Pharma to produce generic AIDS drug
9. Generic Products Compete With GlaxoSmithKline
10. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:
(Date:10/13/2015)... ... 2015 , ... Sir Grout of Greater Boston donated an expansive, seven room ... McDonald House Charities® (RMHC®). This donation was made in an effort to give back ... its inception. , “We believe strongly in the Ronald McDonald House Charities, and they ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Vitamin Angels – a charity that distributes vitamins ... nutritional support - announced its work continues to support ... The UN,s newly established Global Goals - announced on ... up to the Millennium Development Goals established in 2000 ... 17 Global Goals intend to address three primary objectives: ...
(Date:10/13/2015)... -- A minimally-invasive treatment just became available to men suffering ... than 10 years of clinical trials, the Food and ... High Intensity Focused Ultrasound (HIFU), a procedure that can ... and minimizing chances for erectile and urinary dysfunction associated ... pioneering Miami urologist who spearheaded ...
(Date:10/13/2015)... 13, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of ... its previously announced underwritten public offering of 5,000,000 ... purchase up to 3,000,000 shares of the Company,s ... the public of $3.00. The shares of common ...
Breaking Medicine Technology: